ResilEyes Therapeutics

medical devices

About

Resalis Therapeutics is a biotechnology company based in Turin, Italy, with connections to Aalborg University in Denmark and Harvard Medical School. The company specializes in RNA-based therapies aimed at treating complex metabolic disorders, particularly obesity and fatty liver disease. Their lead product candidate, RES-010, is an antisense oligonucleotide designed to inhibit the microRNA miR-22, which plays a crucial role in various metabolic pathways. RES-010 is being developed as a novel therapeutic option for obesity and metabolic-associated fatty liver disease (MAFLD), including metabolic-associated steatohepatitis (MASH). This treatment aims to reprogram metabolic pathways, potentially leading to sustained weight loss and fat reduction in key areas of the body. Currently, RES-010 is in Phase 1 clinical trials, with plans to advance to Phase 2 trials. Resalis Therapeutics targets patients with obesity and metabolic liver diseases, addressing significant unmet medical needs. The company collaborates with healthcare providers and pharmaceutical partners to enhance treatment options in this area, supported by strategic investments, including one from Sanofi.

Technologies

Mobile Friendly Nginx Reviews AI

Keywords

ptsd & pdtx medical equipment manufacturing nutrition pratiques ancestrales magnesium méthodes naturelles offices of all other health practitioners soins énergétiques holistic health d2c sports santé transfert de graisse alimentation saine e-commerce méditation routine quotidienne soins énergétiques traditionnels médecine douce magnetisme à distance health mental health stress codes promo cbd mobility skincare physical therapy beauty healthcare yoga

Location

Paris, Ile-de-France, France

Related Companies

Companies in the same industry